Inhalt
1. Anaissie E, Rex JH, Uzun O, Vartivarian S. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1998;104:238-245.
2. Bodey G, bueltmann B, duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
3. Edwards JE, Jr., Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997;25:43-59.
4. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996;34:489-495.
5. Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998;12:1338-1343.
6. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
7. Jansma J, Vissink A, Spijkervet FKL, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 1992;70:2171-2180.
8. Jarvis WR. Epidemiology of nosocomial infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-1530.
9. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:1611-1625.
10. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996;10:1570-1575.
11. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in candida albicans. Antimicrob Agents Chemother 2001 Jan 2001;45:52-9.
12. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000 Jan 2001;181:309-16.
13. Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin (CAS) versus Amphotericin B deoxycholate (AmB) in the treatment (Rx) of invasive candidiasis (IC) in neutropenic (N) and non-neutropenic (NN) patients (Pts): a multicentre, randomized, double-blind study. 12th ECCMID 2002;O237
14. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998;30:121-129.
15. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (nemis): variations in rates of bloodstream infections due to candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-8.
16. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. niaid mycoses study group and the candidemia study group. Clin Infect Dis 1995;21:994-6.
17. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. infectious diseases society of america. Clin Infect Dis 2000 Apr 2001;30:662-78.
18. Viscoli C, Castagnola E, Giacchino M, et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 1999;35:770-774.
19. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-642.